Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series
Jack J. Scala(Stanford University), Nirali N. Shah(National Institutes of Health), Matthew J. Frank(Stanford Blood Center), Jeffrey S. Huo, Bonnie Yates(National Institutes of Health), Michael J. Eckrich(Levine Children's Hospital), Jan‐Inge Henter(Karolinska University Hospital), Keagan G. Lipak(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Hao‐Wei Wang(Fu Jen Catholic University), Saurabh Dahiya(Stanford University)
Cited by 17
Related Papers
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Perforin Gene Defects in Familial Hemophagocytic Lymphohistiocytosis
|Science|1999|1.2k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society.
|PubMed|1991|765
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744